NICE yes for Roche's Herceptin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is U-turning on earlier draft guidance that turned down Roche's HER2-targeted anticancer Herceptin (trastuzumab) for patients with metastatic gastric cancer. Thanks to a new analysis on a subgroup of patients with high HER2 levels, the institute said today in final draft guidance that the drug can be used on the NHS.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.